These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36816352)

  • 1. Post-COVID-19 health-care utilization: one year after the 2020 first wave in 
Brunei Darussalam.
    Abdullah MS; Asli R; Chong PL; Mani BI; Momin NR; Rahman NA; Chong CF; Chong VH
    Western Pac Surveill Response J; 2023; 14(1):1-9. PubMed ID: 36816352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and demographic characteristics of COVID-19 cases in Brunei Darussalam: comparison between the first and second waves, 2020 and 2021.
    Malik MU; Abdullah MS; Chong PL; Asli R; Mani BI; Rahman N; Momin NR; Lim CA; Wong J; Chong CF; Chong VH
    Western Pac Surveill Response J; 2022; 13(3):1-7. PubMed ID: 36688183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges during the second wave of COVID-19 in Brunei Darussalam: National Isolation Centre to National COVID-19 Hospital.
    Rahman NA; Abdullah MS; Asli R; Chong PL; Mani BI; Chong VH
    Western Pac Surveill Response J; 2022; 13(3):1-7. PubMed ID: 36688181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-COV-2 Screening of Health Care Workers in Brunei Darussalam.
    Trivedi A; Fontelera M; Lai A
    Workplace Health Saf; 2022 Oct; 70(10):452-458. PubMed ID: 35112612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 symptom duration: associations with age, severity and vaccination status in Brunei Darussalam, 2021.
    Tan SY; Teo SP; Abdullah MS; Chong PL; Asli R; Mani BI; Momin NR; Lim ACA; Rahman NA; Chong CF; Chong VH
    Western Pac Surveill Response J; 2022; 13(4):1-9. PubMed ID: 36817502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Care Utilization in the 6 Months Following SARS-CoV-2 Infection.
    Tartof SY; Malden DE; Liu IA; Sy LS; Lewin BJ; Williams JTB; Hambidge SJ; Alpern JD; Daley MF; Nelson JC; McClure D; Zerbo O; Henninger ML; Fuller C; Weintraub E; Saydah S; Qian L
    JAMA Netw Open; 2022 Aug; 5(8):e2225657. PubMed ID: 35960522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-haul COVID: healthcare utilization and medical expenditures 6 months post-diagnosis.
    Koumpias AM; Schwartzman D; Fleming O
    BMC Health Serv Res; 2022 Aug; 22(1):1010. PubMed ID: 35941617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of primary bacterial co-infections among patients with COVID-19 in Brunei Darussalam.
    Bashir A; Abdullah MS; Momin NR; Chong PL; Asli R; Ivan BM; Chong VH
    Western Pac Surveill Response J; 2021; 12(3):65-70. PubMed ID: 34703637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study.
    Ghani H; Ahmad L; Sharif H; Wong J; Bagol S; Alikhan MF; Taib S; Tan CW; Zhu F; Ong XM; Shim CY; Wang Y; Chan SY; Wei Y; Idris F; Naing L; Wang LF; Cunningham AC
    BMJ Open; 2022 Dec; 12(12):e067020. PubMed ID: 36456015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.